Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Emergent BioSolutions Inc.NYSE: EBS
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $11.4M (cash outflow) rose 2750.0% year over year, ahead of the -36.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 90.0% from the prior quarter.
Context
- Financing cash flow amounted to 18.4% of revenue in FY2025, up 0.2 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +2750.0% holds above the trailing-twelve-month pace of -36.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (136.6M) USD
- Year-over-year change
- +28.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (136.6M) | +28.1% |
| FY2024 | 2024-12-31 | (190M) | +64.5% |
| FY2023 | 2023-12-31 | (535.7M) | -211.3% |
| FY2022 | 2022-12-31 | 481.2M | +441.3% |
| FY2021 | 2021-12-31 | (141M) | — |
Financing Cash Flow vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -36.1% is the 9th highest of 11, against a peer median of +13.2%.
- Financing cash flow amounts to 21.8% of revenue for EBS, versus a peer median of 12.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $362.11M USD | +157.4% | +413.4% | — | |
| LTM Mar 2026 | $256.78M USD | -1.3% | +662.8% | — | |
| LTM Mar 2026 | $226.9M USD | +360.2% | — | — | |
| LTM Mar 2026 | $147.6M USD | -36.1% | — | 21.8% | |
| LTM Mar 2026 | $86.39M USD | +284.0% | +107.0% | 171.9% | |
| LTM Mar 2026 | $59.9M USD | +615.4% | +3.5% | 14.3% | |
| LTM Mar 2026 | CA$50.85M CAD | -20.7% | +9.2% | 5.4% | |
| LTM Mar 2026 | $44.12M USD | +1.5% | -1.8% | 47.0% | |
| LTM Mar 2026 | $35.52M USD | -226.0% | +99.1% | 6.9% | |
| LTM Mar 2026 | $10.8M USD | +25.0% | -54.9% | 3.6% | |
| LTM Mar 2026 | $7.03M USD | -1150.0% | — | 12.1% | |
| Peer median (excluding EBS) | — | +13.2% | +54.2% | 12.1% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 230.9M | (211.6M) | (760.5M) | (190.6M) | 52.6M |
| Depreciation & Amortization | 123.8M | 143.3M | 125.1M | 108.8M | 95.8M |
| Deferred Income Tax | 46.9M | (28.6M) | (8.9M) | (5.5M) | (4M) |
| Stock-Based Compensation | 42.4M | 45.1M | 23.1M | 18M | 16.2M |
| Change in Working Capital | (156.4M) | (2.1M) | (70.3M) | 88.7M | (22.4M) |
| Accounts Receivables | (48.2M) | 118.1M | (21.6M) | (24.4M) | 25.5M |
| Inventory | (44M) | (57.1M) | 600K | (24.5M) | (30.3M) |
| Accounts Payables | (2.5M) | (14M) | 10.6M | (33M) | (8.4M) |
| Other Working Capital | (61.7M) | (49.1M) | (59.9M) | 170.6M | (9.2M) |
| Other Non-Cash Items | 33.5M | 19.8M | 485.2M | 39.3M | 32.4M |
| Operating Cash Flow | 321.1M | (34.1M) | (206.3M) | 58.7M | 170.6M |
| Capital Expenditures | (225M) | (115.8M) | (51.6M) | (22.9M) | (13.8M) |
| Acquisitions (Net) | 0 | 0 | 270.2M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (265.5M) | (6.3M) | 148.1M | 83.2M |
| Investing Cash Flow | (225M) | (381.3M) | 212.3M | 125.2M | 69.4M |
| Debt Repayment | (35.9M) | 564.2M | (543.4M) | (198.4M) | (112.5M) |
| Common Stock Issued | 0 | 0 | 8.4M | 9.3M | 2.2M |
| Common Stock Repurchased | (106M) | (82.1M) | 0 | 0 | (24.9M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 900K | (900K) | (700K) | (900K) | (1.4M) |
| Financing Cash Flow | (141M) | 481.2M | (535.7M) | (190M) | (136.6M) |
| Effect of Forex Changes | (300K) | 500K | (1.2M) | 0 | 100K |
| Net Change in Cash | (45.2M) | 66.3M | (530.9M) | (6.1M) | 103.5M |
| Free Cash Flow | 96.1M | (149.9M) | (257.9M) | 35.8M | 156.8M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.